- Home
- SISI vs KTTA Comparison
SISI vs KTTA Comparison
Compare SISI & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- KTTA
- Stock Information
- Founded
- SISI 1997
- KTTA 2020
- Country
- SISI China
- KTTA United States
- Employees
- SISI N/A
- KTTA N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- KTTA Health Care
- Exchange
- SISI Nasdaq
- KTTA Nasdaq
- Market Cap
- SISI 5.6M
- KTTA 5.5M
- IPO Year
- SISI 2016
- KTTA 2021
- Fundamental
- Price
- SISI $5.60
- KTTA $0.81
- Analyst Decision
- SISI
- KTTA
- Analyst Count
- SISI 0
- KTTA 0
- Target Price
- SISI N/A
- KTTA N/A
- AVG Volume (30 Days)
- SISI 97.6K
- KTTA 93.8K
- Earning Date
- SISI 11-13-2025
- KTTA 11-12-2025
- Dividend Yield
- SISI N/A
- KTTA N/A
- EPS Growth
- SISI N/A
- KTTA N/A
- EPS
- SISI N/A
- KTTA N/A
- Revenue
- SISI $9,601,324.00
- KTTA N/A
- Revenue This Year
- SISI N/A
- KTTA N/A
- Revenue Next Year
- SISI N/A
- KTTA N/A
- P/E Ratio
- SISI N/A
- KTTA N/A
- Revenue Growth
- SISI 1133.26
- KTTA N/A
- 52 Week Low
- SISI $1.00
- KTTA $0.65
- 52 Week High
- SISI $271.50
- KTTA $5.45
- Technical
- Relative Strength Index (RSI)
- SISI 43.37
- KTTA 61.44
- Support Level
- SISI $5.42
- KTTA $0.70
- Resistance Level
- SISI $6.27
- KTTA $0.84
- Average True Range (ATR)
- SISI 0.61
- KTTA 0.03
- MACD
- SISI -0.04
- KTTA 0.01
- Stochastic Oscillator
- SISI 12.49
- KTTA 81.57
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).